An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...

Of the children who received dupilumab, 8.9% developed ocular surface complications and 3.4% developed periocular involvement ...

Patients with chronic rhinosinusitis with nasal polyps and uncontrolled asthma experienced greater improvements in lung ...

Regeneron Pharmaceuticals and Sanofi SA have initiated a new clinical study titled ‘An Open-Label, Single-Arm Study to Assess Growth and Bone Mineral Density in Children ≥6 to ...

Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PHOENIX -- ...

Extended dosing of dupilumab in patients with AD has similar efficacy as standard dosing, with no significant affect seen on ocular adverse events.

This article was originally published on Dermatology Times ®. It has been lightly edited. Regardless of dosing interval, dupilumab successfully and steadily reduces immunoglubulin E (IgE) serum levels ...

NASHVILLE, Tennessee — For children with uncontrolled asthma on standard therapies and meeting criteria of a type 2 (T2) inflammatory phenotype, a prospective 1-year extension from a phase 3 trial ...

The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed the safety and efficacy of the drug, which ...